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Heterogeneity, long recognized as a hallmark for cancers, 
provides the platform for clonal evolution to occur. The 
advancement of genome biology, especially next genera­
tion DNA sequencing technology, has started to reveal 
tumor heterogeneity at the gene level and, increasingly, 
the nucleotide level. Deep sequencing of cancer genomes 
in combination with sophisticated clustering algorithms 
is being used to identify subclones with similar genomic 
variant profiles with increasing confidence and resolu­
tion. Comparisons of primary tumor samples with matched 
metastatic samples, xenografts and relapse samples have 
provided clues for delineating subclonal phylogenetic 
evolutionary history, rooted at the primary tumor and 
diverging into its various derivatives [1­7]. Ideally, such 
studies would use single cell sequencing, which provides 
the most detailed picture of tumor heterogeneity and 
clonal evolutionary history. Indeed, this challenging 
technique has recently been successfully used to infer the 
evolutionary history of breast cancer cells based on copy 
number variations [8]. However, the low genome 
coverage and the intrinsic error rate in current DNA 
sequencing technology limit the resolution with which 
genomic variants are detected in these samples. A recent 
study by Snuderl et al. [9] has revealed the mosaic ampli­
fication of multiple receptor tyrosine kinases (RTKs) in 
glioblastoma multiforme (GBM) (Figure 1) and achieved 
single­cell resolution, with regard to the selected target 
genes, in dissecting tumor heterogeneity. The discovery 
of mosaic amplification of RTKs in GBMs has broad 
implications for tumor clonal evolution, the concept of 
driver mutations, and treatment choices.
Mosaic amplification of receptor tyrosine kinases 
in glioblastoma
Amplification of RTK genes, including those encoding 
the epidermal growth factor receptor (EGFR), the vas­
cular endothelial growth factor receptor (VEGFR2), the 
platelet­derived growth factor receptor A (PDGFRA), 
and the oncogenes KIT and MET, drives the tumori­
genesis of GBM through the activation of the mitogen­
activated protein kinase pathway. Usually, only one RTK 
shows high­level amplification in a given GBM sample. 
By analyzing The Cancer Genome Atlas (TCGA) project 
copy number data, Snuderl et al. [9] found, unexpectedly, 
that 6.3% (13 out of 206) of the GBM cases showed simul­
taneous amplification of multiple RTKs. The authors 
were able to confirm the coamplification of MET and 
PDGFRA within the same tumor cells from a single 
original TCGA case by fluorescent in situ hybridization 
(FISH). Snuderl et al. [9] further studied their own GBM 
cohort using FISH to detect gene amplification and 
immunofluorescent staining to detect increased protein 
production. They found that 4.5% (16 out of 350) of 
GBMs have more than one amplified RTK. A genome­
wide copy number assessment, by array comparative 
genomic hybridization, showed that the amplicons were 
local, excluding the probability of coamplification due to 
unusually high chromosomal instability. Unlike the single 
TCGA case, these multiple RTK amplifications were 
present in intermingled subpopulations of tumor cells 
that are all mitotically active.
Nonlinear coevolution of tumor subclones
Snuderl et al. [9] found that in all cases with observed co­
amplifications of RTKs, the CDKN2A and TP53 geno­
types were concordant in each of the subpopulations, 
suggesting that these subpopulations share the same 
precursor and can be considered subclones within each 
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tumor. Not surprisingly, the ratios of subclones with 
different amplified RTKs varied broadly among tumor 
samples. A particularly intriguing finding is the spatial 
distribution of the mosaic subclones within a complete 
GBM brain autopsy. Although the EGFR­ and PDGFRA­
amplified subclones are present at a 60:40 ratio in the 
main tumor mass, the portion infiltrating other tissues 
contained exclusively EGFR­amplified cells. The uneven 
distribution suggests that each population may occupy a 
distinct niche within the tumor microenvironment 
(Figure 1). Furthermore, the coexistence of two subpopu­
la tions with different RTK amplifications could mean a 
similar level of fitness for each of the subclones. It is even 
possible that these subclones may cooperate to achieve 
higher fitness than each of the subclones alone. This 
scenario is very different from a linear clonal evolution 
model in which subclones from the primary clone 
compete for dominance and further mutations in the 
dominant subclone initiate another round of selection. 
The hypothesized cooperation among the subclones 
warrants the survival of the fittest few. In fact, co­
operation among different subpopulations of tumor cells 
is not unprecedented. In GBM tumors with both 
amplified wild­type EGFR (wtEGFR) and an activated 
Figure 1. A nonlinear clonal evolution model derived from the observation of mosaic amplification of receptor tyrosine kinases (RTKs) in 
glioblastoma multiforme (GBM). The primary tumor and all of its derivatives carry the early driver mutation that initiates tumorigenesis. Multiple 
progression driver mutations can occur in a non-linear manner, creating subpopulations with variable levels of fitness. Many times, a dominant 
clone emerges before another round of diversification and selection pushes the clonal evolution forward. However, as illustrated by the coexistence 
of subclones with amplification of different RTKs in some GBMs, subclones may coexist because of either similar fitness levels or a cooperative 
relationship for enhanced tumor growth potential. Individual subclones and different combinations of them may occupy specific niches within the 
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form of this RTK (∆EGFR), the former is typically ex­
pressed at far greater abundance. Inda et al. [10] showed 
that cells with ∆EGFR secrete interleukin­6 and/or 
leukemia inhibitory factor, both of which activate the 
wtEGFR in neighboring cells through the receptor gp130, 
enhancing the rate of tumor growth. Thus, cooperation 
of tumor subclones can be achieved by paracrine signal­
ing and can actively maintain tumor heterogeneity. 
Although other tumor types may conceivably have 
similar paracrine signaling among tumor subclones, 
direct evidence is still lacking. The scarcity of fibroblasts 
in GBMs may be a selection force for subclones that can 
provide mitogenic signals and other forms of support for 
tumor growth that are delivered by the stroma in other 
tumors.
Multiplicity of drivers and therapeutic implications
By using a clever combination of genomic data, FISH, 
immunofluorescent staining and other approaches, 
Snuderl et al. [9] have revealed the mosaic amplification 
of multiple RTKs in GBMs and delineated clonal 
evolution within these tumors in molecular and spatial 
detail. Clonal evolution is generally thought to be driven 
by the driver mutations that provide a selective growth 
advantage. Observations made in this study [9] highlight 
the division of driver mutations into early (initiating) 
drivers and late (progression) drivers. The tumor­initiat­
ing driver, apparently the loss of CDKN2A in the GBMs 
investigated in this study, is expected to be present in all 
tumor cells. The late (or progression) drivers, such as 
EGFR, PDGFRA and MET in this study, can be hetero­
geneous within a single tumor.
The authors [9] also identified a case of salivary duct 
carcinoma with amplification of ERBB2 and PDGFRA in 
separate subclones, suggesting that the mosaic 
amplification of multiple RTKs is not limited to GBMs. 
The coamplification of multiple RTKs in GBMs and other 
tumors may demand treatments targeting multiple RTKs. 
However, if subclones with amplification of different 
RTKs depend on each other for survival and growth, 
hitting one partner may be sufficient to disrupt tumor 
growth. A better understanding of the complex relation­
ships among tumor subclones with amplifications of 
different RTKs and other key genetic alterations would 
guide the selection of the weakest link to target, thus 
achieving the maximal therapeutic benefits with the 
fewest side effects.
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